Reducing the costs of phase III cardiovascular clinical trials
- 1 March 2005
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 149 (3) , 482-488
- https://doi.org/10.1016/j.ahj.2004.04.049
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Lessons Learned From Recent Cardiovascular Clinical Trials: Part ICirculation, 2002
- Gains in Life Expectancy from Medical Interventions — Standardizing Data on OutcomesNew England Journal of Medicine, 1998
- Perspectives on Large-Scale Cardiovascular Clinical Trials for the New MillenniumCirculation, 1997
- Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failureEuropean Heart Journal, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1995
- Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1992
- Using cost‐effectiveness analysis to improve the efficiency of allocating funds to clinical trialsStatistics in Medicine, 1990
- Why do we need some large, simple randomized trials?Statistics in Medicine, 1984